Clinical trials: Genitourinary Syndrome of Menopause (GSM)
Genitourinary Syndrome of Menopause (GSM), Vaginal Dryness
Pilot Study of Individualized Treatment for Genitourinary Syndrome of Menopause in Women After Cancer Treatment
This pilot study is designed to evaluate an individualized approach to the treatment of genitourinary syndrome of menopause (GSM) in women who have undergone oncological treatment.
- Conditions
- Genitourinary Syndrome of Menopause (GSM), Vaginal Dryness, Menopause, Female Cancer Survivors
- Trial name
- NCT07420647
- Testing
- Non-ablative vaginal Er:YAG laser therapy, Standard care
- Where
- Slovenia
- Volunteers
- 65 people
- Sponsor
- Institute of Oncology Ljubljana
Women With Breast Cancer
Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
The goal of this interventional study is to evaluate the effect of Intravaginal Prasterone for the treatment of moderate to severe symptoms of genitourinary syndrome (GSM) due to natural, surgical or treatment-induced menopause…
- Trial name
- PROPOSE (NCT06611514)
- Testing
- Prasterone (DHEA)
- Where
- Italy
- Volunteers
- 95 people
- Sponsor
- European Institute of Oncology
Breast Cancer, Genitourinary Syndrome of Menopause
CO2 Laser Therapy for the Treatment of GSM in Patients With Breast Cancer
Given the need for an effective, non-hormonal treatment for Genitourinary syndrome of menopause GSM) symptoms in breast cancer survivors, the reported efficacy of fractional CO2 laser as such a treatment in retrospective studies…
- Trial name
- NCT04517370
- Testing
- Fractional/Pixel CO2 laser
- Where
- Israel
- Volunteers
- 36 people
- Sponsor
- Hadassah Medical Organization
Genitourinary Syndrome of Menopause
Intravaginal Negative Pressure Medical Device for Treatment of Genitourinary Syndrome of Menopause (GSM)
This pilot study aims to evaluate the safety and effectiveness of the VITA AV Clinical System over a period of up to three months after the last treatment, compared to a sham device.
- Trial name
- NCT06768073
- Where
- 2 sites in United States, Georgia
- Volunteers
- 60 people
- Sponsor
- AVeta Medical
Vaginal Atrophy, Genitourinary Disease
Effect of Hybrid Laser 10600+1540 nm on GSM
The primary objective of the study is to clinically confirm, by comparison with a control group, the performance of the 10600 +1540 nm laser in the improvement of atrophic vaginal epithelium at 3 months after the last laser…
- Trial name
- NCT03956563
- Testing
- Youlaser MT Group 2, Youlaser MT Group 1
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Quanta System, S.p.A.
Menopause
Estrogen and the Urogenital Microbiome in GSM
This is a study of how local estrogen treatment affects the microbiome of the vagina and bladder in postmenopausal women experiencing symptoms as part of "Genitourinary Syndrome of Menopause." The goal is to understand more about…
- Trial name
- NCT03336437
- Testing
- Estradiol vaginal ring
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Genitourinary Syndrome of Menopause (GSM), Vaginal Dryness
To Assess Signs and Symptoms in Women Affected by GSM After One Cycle of Pixel CO2-Alma Fractionated Laser
Genitourinary syndrome of menopause (GSM) occurs in approximately 50% of menopausal women but is both underrecognized and undertreated despite numerous treatment options.
- Conditions
- Genitourinary Syndrome of Menopause (GSM), Vaginal Dryness, Burning, Pain
- Trial name
- NCT05156502
- Testing
- Fractionated Laser (Pixel CO2-Alma), Fractionated Laser (Pixel CO.2-Alma)
- Where
- Italy
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Dr. Filippo Murina
Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis
Photobiomodulation for Vaginal Dysfunctions: Home-Based vs Outpatient Treatment
Vaginal disorders, including vulvovaginal candidiasis (VVC), bacterial vaginosis (BV), and genitourinary syndrome of menopause (GSM), are highly prevalent conditions that significantly affect women's quality of life and sexual…
- Conditions
- Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis, Vulvovaginal Candidiasis (VVC)
- Trial name
- NCT07697768
- Testing
- Blue LED Photobiomodulation
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Patricia Lordelo
Genitourinary Syndrome of Menopause (GSM)
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the…
- Trial name
- NCT07038070
- Testing
- Vaginal estrogen tablet, Via Solv Wellness (Hyaluronic Acid Therapy)
- Where
- United States
- Sponsor
- NYU Langone Health
Genitourinary Syndrome of Menopause (GSM)
Bipolar Radiofrequency for Genitourinary Syndrome of Menopause
This randomized, sham-controlled clinical trial aims to evaluate the efficacy and safety of bipolar radiofrequency in the treatment of genitourinary syndrome of menopause (GSM) in postmenopausal women.
- Trial name
- BRF-GSM (NCT07419035)
- Testing
- Active bipolar radiofrequency therapy
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- University of Castilla-La Mancha
Vaginal Atrophy Patients With GSM
The Effect Of Fractional CO2 Laser Therapy On Cancer Survivors With Genitourinary Syndrome Of Menopause (GSM)
Improvement in cancer therapies has led to an increase in the number of women surviving chemotherapy (and other treatments) and overcoming cancer.
- Trial name
- NCT06318052
- Testing
- The FemTouch delivery system, Gynomunal gel treatment
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Lumenis Be Ltd.
Genitourinary Syndrome of Menopause
Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy
We have recently developed and optimized a vaginal Optical Coherence tomography/angiography endoscopy imaging system. This technology is able to obtain a comprehensive image of the vaginal epithelium, blood vessels, and lamina…
- Trial name
- NCT04737616
- Testing
- CO2 laser, OCT
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Genitourinary Syndrome of Menopause (GSM), Breast Cancer
Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors
Breast cancer survivors (BCS) often face unique challenges during and after treatment, including the onset of menopause-related symptoms.
- Conditions
- Genitourinary Syndrome of Menopause (GSM), Breast Cancer, Vulvovaginal Atrophy, Genitourinary Syndrome of Menopause
- Trial name
- V-light cohort (NCT07563621)
- Testing
- Questionnaires (NRS, DASS-21, EORTC QLQ-C30, EORTC QLQ-BR42, FSFI, FSDS-R)
- Where
- Belgium
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Jessa Hospital
Vulvo Vaginal Atrophy, Genitourinary Syndrome of Menopause (GSM)
Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment
This is a randomized, controlled trial aiming to evaluate the effectiveness of adding vaginal dilators to the treatment of vulvovaginal atrophy.
- Conditions
- Vulvo Vaginal Atrophy, Genitourinary Syndrome of Menopause (GSM), Vaginal Atrophy in Breast Cancer Patients, Vaginal Atrophy Patients With GSM
- Trial name
- NCT06828640
- Testing
- vaginal dilators
- Where
- Belgium
- Volunteers
- 160 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Genitourinary Syndrome of Menopause
Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors
To study the efficacy and safety of intravaginal CO2 laser versus intravaginal Er:YAG laser and sham application in alleviating genitourinary symptoms in patients receiving an aromatase inhibitor as adjuvant treatment of breast…
- Trial name
- LASI (NCT05713435)
- Testing
- intravaginal laser
- Where
- Belgium
- Volunteers
- 162 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Genitourinary Syndrome of Menopause (GSM)
A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause
Non-hormonal alternatives for the treatment of genitourinary syndrome of menopause (GSM) are needed. In this proposed trial, patients who are diagnosed with GSM will be randomized to receive either a hyaluronic acid (HLA) vaginal…
- Trial name
- NCT04544475
- Testing
- Revaree, Estrace
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Menopause, Vaginal Atrophy
CO2 Laser in the Treatment of the GSM - (Genitourinary Syndrome of Menopause) Genitourinary Syndrome of Menopause
Menopause is a woman's hormonal status one year after her ovulatory failure, when the decrease of circulating estrogen levels leads to a group of symptoms named Genitourinary Syndrome of Menopause (GSM), such as: vaginal dryness…
- Conditions
- Menopause, Vaginal Atrophy, Urinary Incontinence
- Trial name
- NCT03939078
- Testing
- CO2 fractional ablative laser
- Where
- Brazil
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Universidade Federal Fluminense
Genitourinary Abnormality, Breast Cancer Female
GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors
The impact of treatment for GSM on the quality of life will be examined for postmenopausal women (defined as last menstrual period > 1 year ago or 6 months ago with FSH >40) who have been diagnosed with breast cancer.
- Conditions
- Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections
- Trial name
- GSM (NCT03185169)
- Testing
- Replens and coconut oil
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Alta Bates Summit Medical Center
Genitourinary Syndrome of Menopause
Impact of Oral Supplementation With Bioactive Collagen Peptides and Other Functional Ingredients
Genitourinary Syndrome of Menopause (GSM), characterized by vaginal dryness, pain, urinary incontinence, and other symptoms, can be mitigated through both hormonal and non-hormonal treatments.
- Trial name
- Maicol (NCT07151482)
- Testing
- Collagendep
- Volunteers
- 43 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Vaginal Atrophy, Atrophic Vaginitis
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment.
- Conditions
- Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)
- Trial name
- ASSIST-VLA (NCT07346287)
- Testing
- 7-940
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stratpharma AG